M34.81 identifies systemic sclerosis (scleroderma) in which the disease process has extended to involve the lungs — most commonly as interstitial lung disease or pulmonary arterial hypertension — as a documented manifestation of the underlying connective tissue disorder.
Verified May 8, 2026 · 5 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 12
- Region
- General
Documentation tips
What should appear in the chart to support M34.81.
Source · Editorial brief grounded in 5 cited references ↓
- Document the specific pulmonary manifestation by name — interstitial lung disease, pulmonary fibrosis, or secondary pulmonary arterial hypertension — to support the 'Code also' additive codes J84.89 or I27.21.
- Record HRCT findings (honeycombing, ground-glass opacities, fibrosis pattern) or PFT results (restrictive pattern, reduced DLCO) that confirm lung involvement; these substantiate both M34.81 and any companion pulmonary code.
- Distinguish systemic sclerosis from circumscribed (localized) scleroderma in the note; the Excludes1 at M34 means L94.0 cannot coexist with M34.81, so the distinction must be clinically clear.
- Confirm whether drug or chemical exposure triggered the scleroderma — if so, M34.2 replaces M34.81 and a causal agent code is required.
- Note the subtype of systemic sclerosis (diffuse cutaneous, limited cutaneous/CREST, overlap) if documented; while it doesn't change the M34.81 assignment, it provides clinical context for medical necessity review.
Related CPT procedures
Procedure codes commonly billed with M34.81. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M34.81 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Defaulting to M34.9 (systemic sclerosis, unspecified) when the record clearly documents lung involvement — this loses the specificity that supports medical necessity for pulmonary services.
- Omitting the mandatory 'Code also' companions J84.89 or I27.21 when interstitial lung disease or secondary pulmonary arterial hypertension is separately documented; CMS billing and coding articles expect these additive codes.
- Assigning M34.81 alongside L94.0 (circumscribed scleroderma) — these are mutually exclusive under the Excludes1 rule at category M34.
- Using M34.81 for drug-induced scleroderma with lung involvement — M34.2 is the correct parent when etiology is documented as drug or chemical exposure.
- Sequencing a pulmonary code (e.g., J84.89) as principal when the underlying cause is systemic sclerosis — M34.81 should lead, with the organ-specific code following.
Clinical context
Source · Editorial summary grounded in 5 cited references ↓
Use M34.81 when the treating physician documents systemic sclerosis with pulmonary involvement, whether that manifests as interstitial lung disease (ILD), pulmonary fibrosis, or secondary pulmonary arterial hypertension. This code lives under the M34.8 'Other forms of systemic sclerosis' parent and is the only code in the M34 category that explicitly captures lung involvement; do not default to M34.9 (unspecified) when the chart documents a pulmonary complication.
The tabular list carries mandatory 'Code also' instructions: if interstitial pulmonary disease is separately documented, add J84.89 (other interstitial pulmonary diseases); if secondary pulmonary arterial hypertension is documented, add I27.21. Both are additive — M34.81 remains the principal or first-listed diagnosis code for the scleroderma, with the pulmonary codes sequenced after it. This code is recognized by CMS as supporting medical necessity for pulmonary stress testing and respiratory care services, making correct assignment directly relevant to coverage determinations.
Excludes1 notes at the M34 category level rule out circumscribed scleroderma (L94.0) and neonatal scleroderma (P83.88) — neither may be coded with M34.81. If the patient's scleroderma was induced by a drug or chemical, use M34.2 instead. If myopathy or polyneuropathy is the documented organ involvement rather than lung disease, use M34.82 or M34.83 respectively.
Sibling codes
Other billable codes under M34.8 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 5 cited references ↓
01When do I add J84.89 alongside M34.81?
02Can I use M34.81 and I27.21 together?
03What is the difference between M34.81 and M34.9?
04Does M34.81 apply to both diffuse and limited (CREST) systemic sclerosis when lung involvement is present?
05Is M34.81 on the CMS covered diagnosis list for pulmonary function testing?
06Can M34.81 and L94.0 appear on the same claim?
07What if the scleroderma was drug-induced and has lung involvement?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026
- 02aapc.comhttps://www.aapc.com/codes/icd-10-codes/M34.81
- 03icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M30-M36/M34-/M34.81
- 04cms.govhttps://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56784&ver=18
- 05cms.govhttps://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=57225&ver=52
Mira AI Scribe
Mira's AI scribe captures the documented pulmonary manifestation (ILD, pulmonary fibrosis, secondary PAH), relevant HRCT or PFT findings, and the treating physician's explicit linkage of lung disease to the underlying systemic sclerosis. This prevents a drop to the unspecified M34.9, ensures the correct 'Code also' companions (J84.89, I27.21) are flagged for coder review, and supports medical necessity for pulmonary stress testing and respiratory care reimbursement.
See how Mira captures M34.81 documentation